1
|
BRAF mutations in hairy-cell leukemia.
|
N Engl J Med
|
2011
|
7.05
|
2
|
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
|
J Clin Oncol
|
2013
|
4.50
|
3
|
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.
|
Proc Natl Acad Sci U S A
|
2008
|
4.26
|
4
|
Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients.
|
Blood
|
2011
|
3.73
|
5
|
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.
|
Nat Genet
|
2012
|
3.43
|
6
|
Prognostic score including gene mutations in chronic myelomonocytic leukemia.
|
J Clin Oncol
|
2013
|
3.10
|
7
|
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
|
Blood
|
2009
|
3.07
|
8
|
Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles.
|
Proc Natl Acad Sci U S A
|
2002
|
3.05
|
9
|
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.
|
Blood
|
2011
|
2.71
|
10
|
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.
|
Blood
|
2009
|
2.41
|
11
|
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
|
J Clin Oncol
|
2010
|
2.29
|
12
|
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
|
J Clin Oncol
|
2006
|
2.22
|
13
|
Prognosis in therapy-related acute myeloid leukemia and impact of karyotype.
|
J Clin Oncol
|
2004
|
2.21
|
14
|
Implications of NRAS mutations in AML: a study of 2502 patients.
|
Blood
|
2006
|
2.20
|
15
|
A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.
|
Haematologica
|
2007
|
2.19
|
16
|
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
|
J Clin Oncol
|
2008
|
2.01
|
17
|
Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
|
J Clin Oncol
|
2009
|
1.98
|
18
|
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
|
Br J Haematol
|
2008
|
1.90
|
19
|
Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.
|
J Exp Med
|
2006
|
1.88
|
20
|
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).
|
Blood
|
2012
|
1.85
|
21
|
Global approach to the diagnosis of leukemia using gene expression profiling.
|
Blood
|
2005
|
1.76
|
22
|
Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).
|
Blood
|
2010
|
1.75
|
23
|
Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression.
|
Blood
|
2006
|
1.74
|
24
|
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.
|
Blood
|
2007
|
1.72
|
25
|
Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
|
Haematologica
|
2005
|
1.69
|
26
|
Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo.
|
Cancer Cell
|
2013
|
1.68
|
27
|
The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.
|
J Clin Invest
|
2005
|
1.68
|
28
|
A novel hierarchical prognostic model of AML solely based on molecular mutations.
|
Blood
|
2012
|
1.64
|
29
|
A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
|
Haematologica
|
2004
|
1.63
|
30
|
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.
|
Blood
|
2011
|
1.56
|
31
|
Molecular characterization of acute leukemias by use of microarray technology.
|
Genes Chromosomes Cancer
|
2003
|
1.55
|
32
|
Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy.
|
Haematologica
|
2005
|
1.55
|
33
|
Diagnostic tool for the identification of MLL rearrangements including unknown partner genes.
|
Proc Natl Acad Sci U S A
|
2004
|
1.53
|
34
|
Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.
|
Leuk Lymphoma
|
2009
|
1.51
|
35
|
The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
|
Haematologica
|
2004
|
1.51
|
36
|
Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop.
|
Genes Chromosomes Cancer
|
2002
|
1.51
|
37
|
Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor.
|
Blood
|
2008
|
1.51
|
38
|
AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases.
|
Blood
|
2003
|
1.49
|
39
|
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.
|
Blood
|
2004
|
1.49
|
40
|
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
|
J Clin Oncol
|
2003
|
1.49
|
41
|
Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML.
|
Leuk Lymphoma
|
2007
|
1.46
|
42
|
Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups.
|
Leuk Lymphoma
|
2012
|
1.45
|
43
|
Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course.
|
Leuk Res
|
2012
|
1.44
|
44
|
Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia.
|
Blood
|
2007
|
1.41
|
45
|
Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.
|
Blood
|
2006
|
1.40
|
46
|
The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.
|
Genes Chromosomes Cancer
|
2013
|
1.39
|
47
|
Reverse transcriptase-polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemia.
|
Leuk Lymphoma
|
2006
|
1.37
|
48
|
Comprehensive mutational profiling in advanced systemic mastocytosis.
|
Blood
|
2013
|
1.35
|
49
|
Molecular genetics in acute myeloid leukemia.
|
Curr Opin Oncol
|
2010
|
1.33
|
50
|
Monitoring of minimal residual disease in acute myeloid leukemia.
|
Cancer
|
2008
|
1.25
|
51
|
Genetic basis of congenital erythrocytosis: mutation update and online databases.
|
Hum Mutat
|
2013
|
1.18
|
52
|
Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies.
|
Blood
|
2012
|
1.18
|
53
|
Diagnostic pathways in acute leukemias: a proposal for a multimodal approach.
|
Ann Hematol
|
2007
|
1.17
|
54
|
Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.
|
Haematologica
|
2012
|
1.17
|
55
|
Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype.
|
Haematologica
|
2009
|
1.17
|
56
|
Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis.
|
Haematologica
|
2008
|
1.17
|
57
|
Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis.
|
Haematologica
|
2009
|
1.16
|
58
|
The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms.
|
Blood
|
2010
|
1.16
|
59
|
Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information.
|
Ann Hematol
|
2005
|
1.14
|
60
|
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia.
|
Haematologica
|
2008
|
1.14
|
61
|
Robustness of amplicon deep sequencing underlines its utility in clinical applications.
|
J Mol Diagn
|
2013
|
1.13
|
62
|
Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression.
|
Cancer Genet Cytogenet
|
2005
|
1.11
|
63
|
Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.
|
Ann Hematol
|
2010
|
1.11
|
64
|
Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile.
|
Genes Chromosomes Cancer
|
2005
|
1.11
|
65
|
Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data.
|
Cancer
|
2010
|
1.11
|
66
|
Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%.
|
Genes Chromosomes Cancer
|
2014
|
1.10
|
67
|
Several lymphoma-specific genetic events in parallel can be found in mature B-cell neoplasms.
|
Genes Chromosomes Cancer
|
2011
|
1.09
|
68
|
Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations.
|
Br J Haematol
|
2011
|
1.09
|
69
|
Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia.
|
Haematologica
|
2005
|
1.09
|
70
|
Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype.
|
Blood
|
2011
|
1.08
|
71
|
Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia.
|
Haematologica
|
2011
|
1.08
|
72
|
KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor.
|
Blood
|
2004
|
1.07
|
73
|
Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.
|
Haematologica
|
2008
|
1.07
|
74
|
Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases.
|
Haematologica
|
2014
|
1.06
|
75
|
Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH.
|
Genes Chromosomes Cancer
|
2002
|
1.06
|
76
|
High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms.
|
Haematologica
|
2012
|
1.04
|
77
|
Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.
|
Haematologica
|
2011
|
1.04
|
78
|
Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia.
|
Br J Haematol
|
2011
|
1.04
|
79
|
Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.
|
Blood
|
2009
|
1.03
|
80
|
Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype.
|
Oncogene
|
2005
|
1.00
|
81
|
ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
|
Genes Chromosomes Cancer
|
2011
|
1.00
|
82
|
Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
|
Genes Chromosomes Cancer
|
2014
|
0.99
|
83
|
Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms.
|
Br J Haematol
|
2010
|
0.98
|
84
|
Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
|
Blood
|
2003
|
0.98
|
85
|
Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC).
|
Blood
|
2010
|
0.98
|
86
|
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.
|
Ann Hematol
|
2013
|
0.98
|
87
|
Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients.
|
Ann Hematol
|
2005
|
0.97
|
88
|
A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia.
|
Blood
|
2002
|
0.97
|
89
|
Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL.
|
Br J Haematol
|
2012
|
0.97
|
90
|
The role of multiparameter flow cytometry for disease monitoring in AML.
|
Best Pract Res Clin Haematol
|
2010
|
0.97
|
91
|
Correlation of protein expression and gene expression in acute leukemia.
|
Cytometry B Clin Cytom
|
2003
|
0.96
|
92
|
A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia.
|
Blood
|
2010
|
0.96
|
93
|
The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
|
Blood
|
2002
|
0.94
|
94
|
Impact of trisomy 8 on expression of genes located on chromosome 8 in different AML subgroups.
|
Genes Chromosomes Cancer
|
2006
|
0.94
|
95
|
Pattern robustness of diagnostic gene expression signatures in leukemia.
|
Genes Chromosomes Cancer
|
2005
|
0.94
|
96
|
TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
|
Br J Haematol
|
2011
|
0.93
|
97
|
Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis.
|
Blood
|
2014
|
0.93
|
98
|
Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia.
|
Cytometry B Clin Cytom
|
2009
|
0.93
|
99
|
Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia.
|
Br J Haematol
|
2005
|
0.92
|
100
|
Transcription factor C/EBPα-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia.
|
Blood
|
2013
|
0.91
|
101
|
Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 cases.
|
PLoS One
|
2013
|
0.90
|
102
|
Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
|
Ann Hematol
|
2009
|
0.90
|
103
|
CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
|
Br J Haematol
|
2013
|
0.90
|
104
|
Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia.
|
Genes Chromosomes Cancer
|
2011
|
0.90
|
105
|
Molecular diagnostics in acute leukemias.
|
Clin Chem Lab Med
|
2009
|
0.90
|
106
|
AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes.
|
Genes Chromosomes Cancer
|
2005
|
0.90
|
107
|
Atypical mRNA fusions in PML-RARA positive, RARA-PML negative acute promyelocytic leukemia.
|
Genes Chromosomes Cancer
|
2010
|
0.90
|
108
|
Acute myeloid leukemia with recurring chromosome abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute myeloid leukemia.
|
Haematologica
|
2003
|
0.89
|
109
|
The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.
|
Ann Hematol
|
2007
|
0.89
|
110
|
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1).
|
Haematologica
|
2008
|
0.89
|
111
|
The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
|
Oncogene
|
2003
|
0.88
|
112
|
Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.
|
Haematologica
|
2003
|
0.88
|
113
|
Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.
|
Haematologica
|
2004
|
0.88
|
114
|
Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
|
Genes Chromosomes Cancer
|
2012
|
0.87
|
115
|
Flow cytometric identification of 76 patients with biclonal disease among 5523 patients with chronic lymphocytic leukaemia (B-CLL) and its genetic characterization.
|
Br J Haematol
|
2013
|
0.87
|
116
|
A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
|
Haematologica
|
2006
|
0.87
|
117
|
Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia.
|
ScientificWorldJournal
|
2011
|
0.87
|
118
|
Impact of integrating clinical and genetic information.
|
In Silico Biol
|
2002
|
0.86
|
119
|
Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.
|
Leuk Lymphoma
|
2014
|
0.86
|
120
|
The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia.
|
Haematologica
|
2005
|
0.86
|
121
|
Distinct sequences on 11q13.5 and 11q23-24 are frequently coamplified with MLL in complexly organized 11q amplicons in AML/MDS patients.
|
Genes Chromosomes Cancer
|
2004
|
0.86
|
122
|
Activating CBL mutations are associated with a distinct MDS/MPN phenotype.
|
Ann Hematol
|
2012
|
0.86
|
123
|
Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.
|
Genes Chromosomes Cancer
|
2006
|
0.86
|
124
|
Treatment of older patients with AML.
|
Crit Rev Oncol Hematol
|
2005
|
0.86
|
125
|
Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
|
Ann Hematol
|
2013
|
0.86
|
126
|
Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.
|
Cancer Genet Cytogenet
|
2010
|
0.85
|
127
|
Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization.
|
Cancer Genet Cytogenet
|
2004
|
0.85
|
128
|
Quantification of rare NPM1 mutation subtypes by digital PCR.
|
Br J Haematol
|
2014
|
0.84
|
129
|
Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study of 124 patients.
|
Br J Haematol
|
2002
|
0.84
|
130
|
Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms.
|
Eur J Haematol
|
2013
|
0.84
|
131
|
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.
|
Ann Hematol
|
2012
|
0.84
|
132
|
Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential.
|
Blood
|
2007
|
0.84
|
133
|
Modern diagnostics in acute leukemias.
|
Crit Rev Oncol Hematol
|
2005
|
0.84
|
134
|
Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters.
|
Genes Chromosomes Cancer
|
2010
|
0.83
|
135
|
A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia.
|
Haematologica
|
2006
|
0.83
|
136
|
Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology.
|
J Mol Diagn
|
2011
|
0.83
|
137
|
Lifelong persistence of AML associated MLL partial tandem duplications (MLL-PTD) in healthy adults.
|
Leuk Res
|
2006
|
0.83
|
138
|
EZH2 mutations and their association with PICALM-MLLT10 positive acute leukaemia.
|
Br J Haematol
|
2012
|
0.83
|
139
|
Rapid diagnostic approach to PML-RARalpha-positive acute promyelocytic leukemia.
|
Hematol J
|
2002
|
0.83
|
140
|
Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia.
|
Cancer
|
2006
|
0.83
|
141
|
Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene.
|
Br J Haematol
|
2014
|
0.82
|
142
|
Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings.
|
Cytometry B Clin Cytom
|
2004
|
0.82
|
143
|
CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia.
|
Haematologica
|
2011
|
0.82
|
144
|
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.
|
Blood
|
2012
|
0.82
|
145
|
Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse.
|
Haematologica
|
2012
|
0.82
|
146
|
Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact.
|
Br J Haematol
|
2013
|
0.82
|
147
|
Chromosomal organization and localization of the human histone deacetylase 9 gene (HDAC9).
|
Biochem Biophys Res Commun
|
2002
|
0.81
|
148
|
Monitoring of minimal residual disease in acute myeloid leukemia.
|
Crit Rev Oncol Hematol
|
2005
|
0.81
|
149
|
Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia.
|
J Natl Cancer Inst
|
2005
|
0.80
|
150
|
Quantitative PCR based minimal residual disease detection in core binding factor leukemias: prognostication and guiding of therapy.
|
Leuk Res
|
2005
|
0.80
|
151
|
Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms.
|
Cytometry B Clin Cytom
|
2013
|
0.80
|
152
|
Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias.
|
Cancer
|
2006
|
0.80
|
153
|
Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase.
|
J Cancer Res Clin Oncol
|
2014
|
0.79
|
154
|
Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia.
|
Cytometry B Clin Cytom
|
2011
|
0.79
|
155
|
The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes.
|
Cancer
|
2009
|
0.79
|
156
|
Isolated epidural chloroma with translocation t(15; 17) successfully treated with chemotherapy and all-trans-retinoic acid.
|
Br J Haematol
|
2003
|
0.79
|
157
|
Tracing the development of acute myeloid leukemia in CBL syndrome.
|
Blood
|
2014
|
0.78
|
158
|
Analysis of site-specific transgene integration following cotransduction with recombinant adeno-associated virus and a rep encodingplasmid.
|
J Gene Med
|
2003
|
0.78
|
159
|
Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia.
|
Cancer Genet Cytogenet
|
2007
|
0.78
|
160
|
Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia.
|
Cancer Genet Cytogenet
|
2010
|
0.78
|
161
|
Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics.
|
Haematologica
|
2012
|
0.78
|
162
|
Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML.
|
Biol Blood Marrow Transplant
|
2010
|
0.78
|
163
|
Childhood B-cell precursor acute lymphoblastic leukaemia in a patient with familial thrombocytopenia and RUNX1 mutation.
|
Br J Haematol
|
2010
|
0.77
|
164
|
Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia.
|
Adv Hematol
|
2011
|
0.77
|
165
|
Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1.
|
Leuk Res
|
2002
|
0.77
|
166
|
Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.
|
Cancer Genet Cytogenet
|
2009
|
0.77
|
167
|
Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases.
|
Cancer Genet Cytogenet
|
2007
|
0.77
|
168
|
Detection of t(14;18)(q32;q21) in B-cell chronic lymphocytic leukemia.
|
Arch Pathol Lab Med
|
2005
|
0.77
|
169
|
Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype.
|
Leuk Res
|
2011
|
0.77
|
170
|
Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes.
|
Biol Blood Marrow Transplant
|
2009
|
0.77
|
171
|
Evaluation of flow cytometric assessment of myeloid nuclear differentiation antigen expression as a diagnostic marker for myelodysplastic syndromes in a series of 269 patients.
|
Cytometry B Clin Cytom
|
2012
|
0.76
|
172
|
Cyclin D1 (CCND1) messenger RNA expression as assessed by real-time PCR contributes to diagnosis and follow-up control in patients with mantle cell lymphoma.
|
Exp Hematol
|
2013
|
0.76
|
173
|
Insight into the molecular pathogenesis of myeloid malignancies.
|
Curr Opin Hematol
|
2007
|
0.76
|
174
|
Inverted duplication dup(1)(q32q21) as sole aberration in lymphoid and myeloid malignancies.
|
Cancer Genet Cytogenet
|
2009
|
0.76
|
175
|
Mutation analysis of the Nijmegen breakage syndrome gene (NBS1) in nineteen patients with acute myeloid leukemia with complex karyotypes.
|
Leuk Lymphoma
|
2003
|
0.76
|
176
|
A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia.
|
Cancer Genet Cytogenet
|
2007
|
0.76
|
177
|
Gene expression profiling as a tool for the diagnosis of acute leukemias.
|
Semin Hematol
|
2003
|
0.76
|
178
|
A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device.
|
Cancer Genet Cytogenet
|
2007
|
0.76
|
179
|
Monitoring of acute myeloid leukemia by flow cytometry.
|
Curr Oncol Rep
|
2003
|
0.76
|
180
|
Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukaemia.
|
Br J Haematol
|
2014
|
0.75
|
181
|
Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia.
|
Leuk Res
|
2012
|
0.75
|
182
|
Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients.
|
Cytometry B Clin Cytom
|
2015
|
0.75
|
183
|
Gene expression profiling as a diagnostic tool in acute myeloid leukemia.
|
Am J Pharmacogenomics
|
2004
|
0.75
|
184
|
[Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)].
|
Med Klin (Munich)
|
2007
|
0.75
|
185
|
A robust molecular pattern for myelodysplastic syndromes in two independent cohorts investigated by next-generation sequencing can be revealed by comparative bioinformatic analyses.
|
Br J Haematol
|
2014
|
0.75
|
186
|
Multiparameter Flow Cytometry Provides Independent Prognostic Information in Patients with Suspected Myelodysplastic Syndromes: A Study on 804 Patients.
|
Cytometry B Clin Cytom
|
2016
|
0.75
|
187
|
A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease.
|
Eur J Haematol
|
2011
|
0.75
|
188
|
Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia.
|
Hematol J
|
2004
|
0.75
|
189
|
Cytogenetics, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction are necessary to clarify the various mechanisms leading to an MLL-AF10 fusion in acute myelocytic leukemia with 10;11 rearrangement.
|
Cancer Genet Cytogenet
|
2003
|
0.75
|
190
|
Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia.
|
Leuk Lymphoma
|
2005
|
0.75
|
191
|
Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells.
|
Leuk Lymphoma
|
2011
|
0.75
|
192
|
Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22).
|
Cancer Genet Cytogenet
|
2006
|
0.75
|
193
|
[Microarrays and gene expression profiling for the diagnosis in leukemia. From research studies to routine application].
|
Med Klin (Munich)
|
2006
|
0.75
|
194
|
Treatment of AML in biological subgroups.
|
Hematology
|
2005
|
0.75
|
195
|
Role of gene expression profiling for diagnosing acute leukemias.
|
Rev Clin Exp Hematol
|
2005
|
0.75
|
196
|
Absence of SCL mutations in myeloid malignancies.
|
Br J Haematol
|
2003
|
0.75
|
197
|
Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease.
|
Onkologie
|
2009
|
0.75
|